Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

189 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-04-30

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this project is to characterize the response TRAP positive patients with Multiple Sclerosis (MS) and to evaluate the sensitivity and specificity of the method in order to develop a second time as a diagnostic tool in this disease. We plan to analyze the response TRAP over a hundred patients with various clinical stages SEP (relapsing, progressive forms) and compared to healthy controls,

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients

NCT02142764

Multiple Sclerosis

COMPLETED NA

From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis

NCT04873492

Multiple Sclerosis

UNKNOWN NA

Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle Progression

NCT05941975

Multiple Sclerosis

RECRUITING NA

EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients

NCT02117375

Multiple Sclerosis

UNKNOWN NA

Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis.

NCT04595799

Multiple Sclerosis

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Relapsing Multiple Sclerosis- group 1

Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.

Group Type OTHER

Trap Myelin Test

Intervention Type DEVICE

Relapsing Multiple Sclerosis- group 2

Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.

Group Type OTHER

Trap Myelin Test

Intervention Type DEVICE

secondary progressive multiple sclerosis- Group 3

Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis

Group Type OTHER

Trap Myelin Test

Intervention Type DEVICE

primary progressive multiple sclerosis- group 4

Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis

Group Type OTHER

Trap Myelin Test

Intervention Type DEVICE

control 1

healthy volunteers

Group Type OTHER

Trap Myelin Test

Intervention Type DEVICE

Control 2

Patients with central or peripheral neurological non-inflammatory, non-autoimmune.

Group Type OTHER

Trap Myelin Test

Intervention Type DEVICE

Control 3

Patients having an autoimmune pathology

Group Type OTHER

Trap Myelin Test

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trap Myelin Test

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* These criteria depend on the subgroup belongs to the patient.
* Signed consent
* Membership of a social security system

Exclusion Criteria

* Whatever the patient group or control:
* Processing immunosuppressive.
* Processing by a monoclonal antibody.
* Previous treatment with an immunosuppressant for a significant period of time (more than 6 months of oral treatment, more than 6 cycles of cyclophosphamide over 3 cures mitoxantrone).
* Carcinomatous pathology known evolving.
* People under guardianship.
* Pregnant women.
* Patients not motivated to study. Known patients with anemia (hemoglobin \<10g/100ml)

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes